"Aminobutyrates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivatives of BUTYRIC ACID that contain one or more amino groups attached to the aliphatic structure. Included under this heading are a broad variety of acid forms, salts, esters, and amides that include the aminobutryrate structure.
| Descriptor ID |
D000613
|
| MeSH Number(s) |
D02.241.081.114.500 D12.125.190
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Aminobutyrates".
Below are MeSH descriptors whose meaning is more specific than "Aminobutyrates".
This graph shows the total number of publications written about "Aminobutyrates" by people in this website by year, and whether "Aminobutyrates" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 6 | 0 | 6 |
| 2015 | 7 | 0 | 7 |
| 2016 | 11 | 0 | 11 |
| 2017 | 5 | 2 | 7 |
| 2018 | 4 | 4 | 8 |
| 2019 | 9 | 1 | 10 |
| 2020 | 9 | 2 | 11 |
| 2021 | 4 | 7 | 11 |
| 2022 | 0 | 8 | 8 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Aminobutyrates" by people in Profiles.
-
Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial. Circ Heart Fail. 2023 03; 16(3):e010111.
-
Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol. 2022 09 20; 80(12):1130-1143.
-
Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials. Cardiovasc Diabetol. 2022 06 18; 21(1):110.
-
Angiotensin-converting enzyme inhibitor therapy after heart transplant: From molecular basis to clinical effects. Clin Transplant. 2022 07; 36(7):e14696.
-
Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFrEF. JACC Heart Fail. 2022 06; 10(6):415-427.
-
Atrial Fibrillation in Heart?Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. JACC Heart Fail. 2022 05; 10(5):336-346.
-
Natriuretic peptide-based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON-HF. Eur J Heart Fail. 2022 04; 24(4):672-677.
-
Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF. Eur J Heart Fail. 2022 03; 24(3):551-561.
-
Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. Eur J Heart Fail. 2022 09; 24(9):1591-1598.
-
Inhibition of neprilysin with sacubitril without RAS blockage aggravates renal disease in Dahl SS rats. Ren Fail. 2021 Dec; 43(1):315-324.